Drug: Copanlisib (Bayer)
Status: Granted priority review for the treatment of relapsed or refractory follicular lymphoma patients who have received at least two prior therapies
Significant Information:
- Intravenous PI3K inhibitor
- Based on results from the Phase II CHRONOS-1 trial, which showed that copanlisib achieved an objective response rate of 59% with durable responses
FDA History: Granted fast track and orphan drug designation for this indication
—Based on a company press